**Question:** Which of the following is not used for tardive dyskinesia?

A. Atypical antipsychotics (e.g., clozapine, olanzapine, quetiapine)
B. Benztropine mesylate
C. Fluoxetine
D. Donepezil

**Correct Answer: C. Fluoxetine**

**Core Concept:** Tardive dyskinesia is a movement disorder that can develop in patients taking antipsychotic medications, particularly typical antipsychotics like chlorpromazine and fluphenazine. The condition is characterized by involuntary, repetitive, and often choreiform movements of the face, tongue, and limbs. It is a side effect of prolonged or excessive exposure to dopamine-blocking agents, which act on the dopamine D2 receptors in the basal ganglia.

**Why the Correct Answer is Right:** Benztropine mesylate is a peripherally acting dopamine D2 antagonist, which is used to treat tardive dyskinesia and its associated symptoms. By blocking dopamine D2 receptors in the periphery, it helps in reducing the extrapyramidal side effects of antipsychotic medications, including tardive dyskinesia.

**Why Each Wrong Option is Incorrect:**

A. Atypical antipsychotics (e.g., clozapine, olanzapine, quetiapine) are also dopamine D2 antagonists, but they are considered "atypical" due to their differing side effect profiles and binding properties. They can also cause tardive dyskinesia, although their incidence is lower compared to typical antipsychotics.

B. Benztropine mesylate is a peripherally acting dopamine D2 antagonist, making it effective in treating tardive dyskinesia and extrapyramidal symptoms associated with antipsychotic medications.

C. Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) used primarily for treating depression, anxiety disorders, and obsessive-compulsive disorders. It is not an antipsychotic medication or a dopamine D2 antagonist, making it ineffective in treating tardive dyskinesia, as it does not target the dopaminergic system directly or indirectly.

D. Donepezil is a cholinesterase inhibitor used primarily for Alzheimer's disease and mild cognitive impairment. It is not an antipsychotic medication or a dopamine D2 antagonist, making it ineffective in treating tardive dyskinesia, as it does not target the dopaminergic system directly or indirectly.

**Clinical Pearl:** Tardive dyskinesia is a complex neurological disorder, and its treatment depends on the causative agent and its duration of exposure. In some cases, a combination of antipsychotic medications and dopamine D2 antagonists may be used. However, the question specifically asks for a treatment option that is not used for tardive dyskinesia. In this case, the correct answer is **Fluoxetine** because it does not target the dopaminergic system directly or indirectly.